Permira Is Said to Weigh €3 Billion-Plus Sale of Neuraxpharm

Permira is considering a sale of Neuraxpharm in a deal that could value the pharmaceutical company that focuses on central nervous system disorders at €3 billion ($3.5 billion) to €4 billion, according to people familiar with the matter.